FDA Grants Accelerated Approval to Brukinsa for Relapsed or Refractory Follicular Lymphoma

The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) with obinutuzumab (Gazyva, Genentech) for ...

MARCH 8, 2024

Some Chemoimmunotherapy Regimens May Reactivate HBV in B-Cell NHL

Data from two phase 3 studies of patients with B-cell non-Hodgkin lymphoma (NHL) with resolved hepatitis B virus ...

FEBRUARY 11, 2019

FDA Approves Imbruvica With Gazyva for First-Line CLL Treatment

The labeling for ibrutinib (Imbruvica, Pharmacyclics/Janssen) has been expanded to include use with obinutuzumab ...

FEBRUARY 4, 2019

FDA Approves Gazyva for Previously Untreated Advanced FL

The FDA granted regular approval to obinutuzumab (Gazyva, Genentech) for use in treatment-naive adults with stage ...

NOVEMBER 21, 2017

Obinutuzumab + CHOP Fails To Beat R-CHOP for DLBCL

Obinutuzumab failed to produce a PFS advantage over rituximab when both drugs were combined with the standard CHOP ...

FEBRUARY 15, 2017

Obinutuzumab Increased OS In Refractory Indolent NHL Pts

San Diego—Obinutuzumab plus bendamustine followed by obinutuzumab maintenance provides an overall survival ...

FEBRUARY 9, 2017

ASH Report: Obinutuzumab Beats Rituximab in Follicular Lymphoma

San Diego—For front-line therapy of follicular lymphoma (FL), an obinutuzumab-based induction and maintenance ...

JANUARY 30, 2017

Obinutuzumab Approved for Follicular Lymphoma

The therapy was approved for use in combination with bendamustine followed by obinutuzumab monotherapy for the ...

FEBRUARY 26, 2016